Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOPES: VM202 for Opioid-Dependent Painful Diabetic Neuropathy
NCT04087941Phase 2Withdrawn
- Sponsor
- Brigham and Women's Hospital
- Start
- Nov 2019
- Primary completion
- Dec 2022
- Modality
- Gene Editing, Gene Silencing, Plasmid DNA
- Countries
- 1
01
Overview
A Phase 2 trial of Engensis in diabetic peripheral neuropathy (DPN), sponsored by Brigham and Women's Hospital. Planned start Nov 2019; status: withdrawn.
02
Drugs
Engensis
03
Conditions
diabetic peripheral neuropathy (DPN)
Beyond the preview
Go deeper on NCT04087941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04087941.